ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Keyword Index

Click a keyword to view all the abstracts on this site tagged with that keyword.

  • Mannose binding lectin (MBL)
  • Mannose binding lectin (MBL) and polymorphism
  • Manual Muscle testing
  • marijuana
  • marijuana and outcomes
  • marijuana and pain management
  • marijuana and population studies
  • marijuana and rheumatic disease
  • Marketing
  • MAS
  • massage
  • mast cell
  • Mast cells
  • mast cells and osteoarthritis
  • mast cells and rheumatoid arthritis (RA)
  • mast cells and salivary gland
  • mast cells and scleroderma
  • mast cells and spondylarthritis
  • mast cells and tumor necrosis factor (TNF)
  • mast cells and type II collagen
  • mast cells and vasculitis
  • matrix metalloproteinase (MMP)
  • matrix metalloproteinase (MMP) and chemokines
  • matrix metalloproteinase (MMP) and cytokines
  • matrix metalloproteinase (MMP) and mesenchymal stem cells
  • Matrix metalloproteinase (MMP) and methotrexate (MTX)
  • matrix metalloproteinase (MMP) and osteoarthritis
  • matrix metalloproteinase (MMP) and rheumatoid arthritis
  • matrix metalloproteinase (MMP) and rheumatoid arthritis (RA)
  • matrix metalloproteinase (MMP) and scleroderma
  • matrix metalloproteinase (MMP) and signal transduction
  • matrix metalloproteinase (MMP) and synovium
  • MBDA and cytokines
  • MDA
  • MDL-1
  • meaningful use
  • measure
  • measure and methotrexate (MTX)
  • measure and osteoarthritis
  • measure and pain
  • measure and patient outcomes
  • measure and pediatric rheumatology
  • measure and physical activity
  • measure and psoriatic arthritis
  • measure and quality improvement
  • measure and rheumatoid arthritis (RA)
  • measure and scleroderma
  • measure and severity
  • measure and systemic lupus erythematosus (SLE)
  • Measurement
  • Measurement Instrument
  • mechanisms
  • mechanisms and monoclonal antibodies
  • mechanisms and osteoarthritis
  • mechanisms and osteoclasts
  • mechanisms and pediatric rheumatology
  • mechanisms and proteomics
  • mechanisms and rheumatoid arthritis
  • mechanisms and rheumatoid arthritis (RA)
  • mechanisms and scleroderma
  • mechanisms and systemic lupus erythematosus (SLE)
  • mechanisms and tofacitnib
  • mechanisms and treatment options
  • mechanosensing and fibrosis
  • Mediation
  • mediation and pain
  • mediation and physical function
  • mediation and rheumatoid arthritis (RA)
  • mediation and systemic lupus erythematosus (SLE)
  • Mediation Model
  • medical
  • medical and educational innovation
  • medical and educational research
  • medical and Fellow-In-Training
  • medical and fellowship programs
  • medical and fibromyalgia
  • medical and gout
  • medical and joint procedures
  • medical and musculoskeletal curriculum
  • medical and musculoskeletal disorders
  • medical and osteoarthritis
  • medical and osteoporosis
  • medical and pediatric rheumatology
  • medical and qualitative
  • medical and rheumatoid arthritis (RA)
  • medical and rheumatologic disease
  • medical and trainee
  • medical and ultrasound
  • medical and vitamins
  • medical and young adults
  • medical education
  • medical education and Contraception
  • medical education and educator
  • medical education and musculoskeletal curriculum
  • medical education and pediatric rheumatology
  • Medical education and quality improvement
  • medical education and rheumatic education
  • medical education and trainee
  • Medical education and ultrasonography
  • medical management
  • medical management and qualitative
  • medical necessity
  • medical necessity and biologic drugs
  • Medical school
  • Medical school and education
  • medical transition
  • Medicare
  • Medicare and cardiovascular disease
  • Medicare and laboratory tests
  • Medicare and psoriatic arthritis
  • Medicare and quality of care
  • Medicare and rheumatoid arthritis (RA)
  • Medicare and systemic lupus erythematosus (SLE)
  • medication
  • medication access and Disease Activity
  • medication adherence
  • medication and beliefs
  • medication and education
  • medication and myositis
  • medication and osteoporosis
  • medication and patient engagement
  • medication and pediatric rheumatology
  • medication and pharmacists
  • medication and pregnancy
  • medication and qualitative
  • medication and quality improvement
  • medication and registry
  • medication and remission
  • medication and rheumatic disease
  • medication and rheumatoid arthritis (RA)
  • medication and risk
  • medication and skill development
  • medication and steroids
  • medication and systemic lupus erythematosus (SLE)
  • medication and treatment
  • medication and treatment options
  • medication and uveitis
  • medication and vasculitis
  • medication response
  • medication side effects
  • medication side effects and pseudogout
  • medication side effects and quality of life
  • medication side effects and rheumatic disease
  • medication side effects and rheumatoid arthritis (RA)
  • medication side effects and self-management
  • medication side effects and systemic sclerosis
  • medication side effects and treatment guidlelines
  • Medications
  • MEFV
  • MEFV variant
  • meloxicam
  • memory
  • memory and neurology
  • memory and synovitis
  • memory and systemic lupus erythematosus (SLE)
  • Meniscal Injury
  • meniscectomy
  • Meniscectomy and osteoarthritis
  • meniscus
  • meniscus and osteoarthritis
  • meniscus and osteonecrosis
  • menopause
  • menopause and autoantibodies
  • menopause and musculoskeletal disorders
  • menopause and osteoporosis
  • menopause and rheumatoid arthritis (RA)
  • menopause and women's health
  • mental health
  • mental health and online resources
  • mental health and pediatric rheumatology
  • mental health and pediatrics
  • mental health and psychiatric
  • mental health and Qualitative Research
  • mental health and rheumatoid arthritis (RA)
  • mental health and systemic sclerosis
  • Mentor
  • mentor and professional development
  • Mer
  • Mesenchymal stem cells
  • mesenchymal stem cells and cell transplantation
  • mesenchymal stem cells and mitochondria
  • Mesenchymal stem cells and osteoarthritis
  • mesenchymal stem cells and osteoblasts
  • mesenchymal stem cells and osteoporosis
  • mesenchymal stem cells and rheumatoid arthritis
  • mesenchymal stem cells and rheumatoid arthritis (RA)
  • mesenchymal stem cells and Senescent Cells
  • mesenchymal stem cells and spondylarthritis
  • mesenchymal stem cells and spondylarthropathy
  • mesenchymal stem cells and synovial cells
  • Mesenchymal stem cells and systemic lupus erythematosus (SLE)
  • mesenchymal stem cells and systemic sclerosis
  • mesenchymal stem cells and therapy
  • mesenchymal stem cells and tissue engineering
  • mesenchymal stem cells and transcription factor
  • mesenchymal stem cells and treatment
  • Mesna
  • messenger RNA (mRNA)
  • messenger RNA (mRNA) and rheumatoid arthritis (RA)
  • messenger RNA (mRNA) and tumor necrosis factor (TNF)
  • First |
  • « Previous Page
  • 33
  • 34
  • 35
  • 36
  • 37
  • [38]
  • 39
  • 40
  • 41
  • 42
  • 43
  • Next Page »
  • | Last
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology